semaglutide mash fda approval FDA Approval of Semaglutide for MASH Marks a Turning Point in Liver Care

GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat MASH (Metabolic Dysfunction–Associated

20.40

★★★★☆4.8 (126)

WEGOVY GETS APPROVAL: The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic Dysfunction-Associated Steatohepatitis), adding to a long list of benefits

21.12

★★★★★4.9 (98)

Semaglutide Gets FDA Greenlight for MASH

23.59

★★★★★5.0 (157)

Novo Nordisk has changed the GLP-1 narrative. Semaglutide (Wegovy) becoming the first FDA-approved GLP-1 therapy for MASH proves this is no longer only about weight loss. GLP-1s are evolving into broad metabolic

28.89

★★★★★4.7 (84)

Ozempic and Wegovy ingredient may reverse signs of liver disease

25.56

★★★★★4.9 (203)

The FDA has granted accelerated approval for Wegovy (semaglutide 2.4 mg, once‑weekly) to treat metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2–F3) without cirrhosis. This is standout

24.18

★★★★★5.0 (176)

FDA Approves Semaglutide to Treat MASH With Moderate to Advanced Fibrosis

28.80

★★★★★4.8 (132)